Updated results of the SOFT study: A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/I-LV/oxaliplatin (mFOLFOX6) plus bevacizumab in patients with metastatic colorectal cancer (mCRC).

被引：1

作者：

Nakamura, Masato

Yamada, Yasuhide

Takahari, Daisuke

Matsumoto, Hiroshi

Baba, Hideo

Yoshida, Kazuhiro

Yoshida, Motoki

Iwamoto, Shigeyoshi

Shimada, Ken

Komatsu, Yoshito

Sasaki, Yasutsuna

Satoh, Taroh

Takahashi, Keiichi

Mishima, Hideyuki

Muro, Kei

Watanabe, Masahiko

Sakata, Yuh

Morita, Satoshi

Shimada, Yasuhiro

Sugihara, Kenichi

机构：

[1] Aizawa Hosp, Matsumoto, Nagano, Japan

[2] Natl Canc Ctr, Gastrointestinal Med Oncol Div, Tokyo, Japan

[3] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi 464, Japan

[4] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan

[5] Kumamoto Univ, Kumamoto, Japan

[6] Gifu Univ, Sch Med, Dept Surg Oncol, Gifu 500, Japan

[7] Osaka Med Coll Hosp, Ctr Canc Chemotherapy, Osaka, Japan

[8] Kansai Med Univ, Takji Hosp, Dept Surg, Moriguchi, Osaka 570, Japan

[9] Saitama Med Univ, Hidaka, Japan

[10] Hokkaido Univ Hosp, Dept Canc Ctr, Sapporo, Hokkaido 060, Japan

[11] Showa Univ, Tokyo, Japan

[12] Osaka Univ, Osaka, Japan

[13] Komagome Hosp, Dept Surg, Tokyo Metropolitan Canc, Tokyo, Japan

[14] Komagome Hosp, Ctr Infect Dis, Tokyo, Japan

[15] Aichi Med Univ, Unit Canc Ctr, Nagakute, Aichi 48011, Japan

[16] Kitasato Univ, Sch Med, Sagamihara, Kanagawa 228, Japan

[17] Misawa City Hosp, Misawa, Japan

[18] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan

[19] Tokyo Med & Dent Univ, Grad Sch, Dept Surg Oncol, Tokyo, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.3586

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3586

引用

页数：1

共 50 条

[41] Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
Kabbinavar, F
Hurwitz, HI
Fehrenbacher, L
Meropol, NJ
Novotny, WF
Lieberman, G
Griffing, S
Bergsland, E
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) : 60 - 65
[42] Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan (IRI) plus bevacizumab (Bmab) versus mFOLFOX6 or CapeOX plus Bmab as first-line treatment for metastatic colorectal cancer (mCRC)
Yuki, Satoshi
Gamoh, Makio
Denda, Tadamichi
Takashima, Atsuo
Takahashi, Shin
Nakamura, Masato
Ohori, Hisatsugu
Yamaguchi, Tatsuro
Kobayashi, Yoshimitsu
Baba, Hideo
Kotake, Masanori
Amagai, Kenji
Kondo, Hitoshi
Shimada, Ken
Sato, Atsushi
Ishioka, Chikashi
Komine, Keigo
Ouchi, Kota
Morita, Satoshi
Komatsu, Yoshito
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[43] Treatment outcome according to tumor RAS mutation status in TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer
Komatsu, Y.
Takashima, A.
Denda, T.
Gamoh, M.
Iwanaga, I.
Shimodaira, H.
Nakamura, M.
Yamaguchi, T.
Takahashi, H.
Kobayashi, K.
Tsuda, M.
Kobayashi, Y.
Baba, H.
Kotake, M.
Ishioka, C.
Sato, A.
Yuki, S.
Morita, S.
Takahashi, S.
Shimada, K.
ANNALS OF ONCOLOGY, 2017, 28
[44] PHASE II STUDY OF S-1, ORAL LEUCOVORIN, OXALIPLATIN AND BEVACIZUMAB COMBINATION THERAPY (SOL plus BV; SOLA) IN PATIENTS WITH UNRESECTABLE METASTATIC COLORECTAL CANCER (MCRC)
Miyata, Y.
Nishina, T.
Kato, T.
Yamazaki, K.
Yoshino, T.
Esaki, T.
Moriwaki, T.
Hyodo, I.
ANNALS OF ONCOLOGY, 2012, 23 : 131 - 131
[45] Phase II study of S-1, oral leucovorin, oxaliplatin, and bevacizumab combination therapy (SOL plus BV; SOLA) in patients with unresectable metastatic colorectal cancer (mCRC).
Kato, Takeshi
Nishina, Tomohiro
Yamazaki, Kentaro
Yoshino, Takayuki
Miyata, Yoshinori
Esaki, Taito
Moriwaki, Toshikazu
Hyodo, Ichinosuke
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
[46] Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801)
Keisuke Miwa
Eiji Oki
Yasunori Emi
Hiroshi Saeki
Tetsuya Kusumoto
Yoshito Akagi
Yutaka Ogata
Hironori Samura
Shoji Tokunaga
Hiroshi Ishikawa
Takaho Tanaka
Susumu Sueyoshi
Hidefumi Higashi
Hiroyuki Matsuda
Tetsuo Touyama
Yoshihiko Maehara
International Journal of Clinical Oncology, 2016, 21 : 110 - 117
[47] Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.
Yoshino, Takayuki
Watanabe, Jun
Shitara, Kohei
Yasui, Hirofumi
Ohori, Hisatsugu
Shiozawa, Manabu
Yamazaki, Kentaro
Oki, Eiji
Sato, Takeo
Naitoh, Takeshi
Komatsu, Yoshito
Kato, Takeshi
Hihara, Masamitsu
Soeda, Junpei
Yamamoto, Kouji
Akagi, Kiwamu
Ochiai, Atsushi
Uetake, Hiroyuki
Tsuchihara, Katsuya
Muro, Kei
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
[48] Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801)
Miwa, Keisuke
Oki, Eiji
Emi, Yasunori
Saeki, Hiroshi
Kusumoto, Tetsuya
Akagi, Yoshito
Ogata, Yutaka
Samura, Hironori
Tokunaga, Shoji
Ishikawa, Hiroshi
Tanaka, Takaho
Sueyoshi, Susumu
Higashi, Hidefumi
Matsuda, Hiroyuki
Touyama, Tetsuo
Maehara, Yoshihiko
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (01) : 110 - 117
[49] Early Results of Phase II Trial of Neoadjuvant Chemotherapy with S-1 and Oxaliplatin Plus Bevacizumab for Colorectal Liver Metastasis
Uehara, K.
Goto, H.
Hiramatsu, K.
Kobayashi, S.
Sakamoto, E.
Maeda, A.
Takeuchi, E.
Okada, Y.
Tojima, Y.
Yamamoto, R.
Okamoto, Y.
Nagino, M.
ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : S74 - S74
[50] PEAK: A randomized phase II study to compare the efficacy of panitumumab plus mFOLFOX6 to bevacizumab plus mFOLFOX6 in patients (pts) with previously untreated, unresectable metastatic colorectal cancer (mCRC) expressing wild-type KRAS
Schwartzberg, L. S.
Wagner, V. J.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

← 1 2 3 4 5 →